Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. - Wikidata - wikimedia - TriplyDB

Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort.

Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort.

http://www.wikidata.org/entity/Q43633425

about

Infliximab dosing patterns in a sample of patients with Crohn's disease: results from a medical chart review The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation.Progress in the treatment and outcome of pediatric inflammatory bowel disease patients.A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab.Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature.Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.Practical application of anti-TNF therapy for luminal Crohn's disease.Antitumor necrosis factor treatment for pediatric inflammatory bowel disease.Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?Medical therapy for pediatric inflammatory bowel disease.Optimizing biological therapy in Crohn's disease.Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease.Inflammatory bowel disease therapies and gut function in a colitis mouse model.The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease.Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease.Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version).Differential effects of nutritional and non-nutritional therapies on intestinal barrier function in an in vitro model.

P2860

Q33724975-8AF8AE6A-AD1C-4A17-95C2-A599A6E02120 Q34152778-D527AE68-B981-42B5-BAD7-4872C1664B06 Q35634488-88405629-7872-4A2B-9704-298C1000977B Q36056969-3476AE28-D53D-41A5-BEDB-4EF4EDD81858 Q37373219-3971D443-DD08-40FE-8DC9-B27EEE6D442B Q37463702-E50EADC3-EB72-4A27-A202-69E8FE2C1CC8 Q37573910-775FACDC-EFAC-421A-932B-CE2C151DE63A Q37609746-29A52B79-C81A-4331-A890-EB6F8DAE8A78 Q37820898-A9578584-9A40-4BFA-B512-D3A643EBDCCC Q37845327-4B0FFFC3-D93B-4B5D-8654-180654F80B55 Q37936394-9A2A693F-D938-4EFC-BCAE-2F304CB5BDA7 Q37965581-50E28BF8-8D52-4A46-9D81-F42CBEFBF8F0 Q37986622-C9CFEA32-18F7-432F-8F58-FDE7277DE98D Q38608158-1CE802E8-DDF4-4381-966C-C0D6506BAA4B Q38919270-77018329-D0B5-4CB6-BC9B-D6E03A29C50D Q42288030-5478719B-20EE-471F-9BD5-58C9662252DE Q43590711-38CA4329-6CD3-4214-BEA3-17259F213AAD Q51138123-B915C169-BA17-487E-94B9-D5B6851FFA5B Q54144614-97D947B0-B865-43BB-B0EA-FFA70D5A452C Q54346274-75AA9B86-2089-45E1-99E4-63628E70FCB3

P2860

Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort.

http://www.wikidata.org/entity/Q43633425

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Infliximab dependency in pedia ...... ow-up of an unselected cohort.

@en

Infliximab dependency in pedia ...... ow-up of an unselected cohort.

@nl

type

label

Infliximab dependency in pedia ...... ow-up of an unselected cohort.

@en

Infliximab dependency in pedia ...... ow-up of an unselected cohort.

@nl

prefLabel

Infliximab dependency in pedia ...... ow-up of an unselected cohort.

@en

Infliximab dependency in pedia ...... ow-up of an unselected cohort.

@nl

P1433

Q43633425-78169DDF-A61D-4B27-B83D-483ECD3EE7B7

P1476

Q43633425-B345A2F5-F5D1-4556-A8CF-F88568F0B235

P2093

Q43633425-2489AADF-B8EE-470B-9FBE-C7B2150D1940

Q43633425-2D83D72B-9E41-4FCC-AE62-674C78975528

Q43633425-37BDFC60-69DC-45BF-9820-4CA92ACDA67C

Q43633425-52105040-689F-42D7-AD31-16E4CCC642BD

Q43633425-9537DF0A-ED33-44F2-BF42-B9B619C48621

Q43633425-97A8F9BB-1EBC-477A-B62A-952C2928298A

Q43633425-9861D8A5-3CFE-49EC-ABEC-5F6D3D8D2E2F

Q43633425-A0334472-9D73-47C0-90CD-83A0B25D0443

Q43633425-B31418DE-02EB-405A-8D71-9ADF3B391E54

Q43633425-DB1F3E80-9FEC-4833-A791-450B710BE94A

P2860

Q43633425-0A11B0E5-C969-4075-B4AB-57F2584E0FF9

Q43633425-239505EE-2389-4B33-952A-44ABE75C1FC5

Q43633425-27BA3847-E8D1-4716-93CE-59E3A496EB22

Q43633425-3B26C960-BDCF-4C3E-969E-886DBE6A93D9

Q43633425-3FA6A344-0468-472B-BB6D-1FE1FD1258DF

Q43633425-471D4DC5-29BB-405B-8477-D7670E83CA0B

Q43633425-542C45AB-F266-4454-AEA9-7697A0B6A49B

Q43633425-6C4083C8-29D1-461C-A51C-F0420DE2CF2F

Q43633425-764F3E18-93B3-4435-9BA6-33049E1359EC

Q43633425-7E4E8383-60AF-4FC2-9A5C-83126D6B7304

P304

Q43633425-61CD8C05-8671-41C0-A445-06F89C5E4AE7

P31

Q43633425-FE73A157-43F0-4650-9777-15E26C68FBA6

P356

Q43633425-25AD3B95-94A2-47C7-A9A6-4BE8F1011D53

P433

Q43633425-4DA6838A-A523-408E-81CD-100C2E745C45

P478

Q43633425-DDEB6D8D-46B7-413A-A35F-A8C2DF477915

P50

Q43633425-D66D242D-05D8-4553-B6C0-D271BD1BC695

P577

Q43633425-F14A5167-0CC6-4371-AF82-971B5C44E915

P5875

Q43633425-4992EDBD-EF14-4A61-9420-DF94CD8F7426

P698

Q43633425-AF8E420B-F2A0-4723-84BE-FAC78AD041AB

P356

P1433

Inflammatory Bowel Diseases

P1476

Infliximab dependency in pedia ...... ow-up of an unselected cohort.

@en

P2093

Carolien F M Gijsbers

http://www.w3.org/2001/XMLSchema#string

Edmond H H M Rings

http://www.w3.org/2001/XMLSchema#string

Freddy T M Kokke

http://www.w3.org/2001/XMLSchema#string

Gerard M Damen

http://www.w3.org/2001/XMLSchema#string

J Hans Hoekstra

http://www.w3.org/2001/XMLSchema#string

Joachim J Schweizer

http://www.w3.org/2001/XMLSchema#string

Johanna C Escher

http://www.w3.org/2001/XMLSchema#string

Lissy de Ridder

http://www.w3.org/2001/XMLSchema#string

Marc A Benninga

http://www.w3.org/2001/XMLSchema#string

Obbe F Norbruis

http://www.w3.org/2001/XMLSchema#string

P2860

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Infliximab maintenance therapy for fistulizing Crohn's disease

Safety of infliximab treatment in pediatric patients with inflammatory bowel disease.

Infliximab for the treatment of fistulas in patients with Crohn's disease.

Use of infliximab in the treatment of Crohn's disease in children and adolescents.

Use of infliximab in pediatric patients with inflammatory bowel disease.

Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model.

Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center.

Infliximab use in children and adolescents with inflammatory bowel disease.

Avoidance of steroids by the early use of infliximab and 6-mercaptopurine in an adolescent with active Crohn's colitis.

P304

353-358

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IBD.20329

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

C M Frank Kneepkens

P577

2008-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5778054

http://www.w3.org/2001/XMLSchema#string

P698

18069674

http://www.w3.org/2001/XMLSchema#string